<DOC>
	<DOC>NCT00237263</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of the long-term treatment of entacapone in patients with Parkinson's disease with end-of-dose wearing-off. This study is not recruiting patients in the United States.</brief_summary>
	<brief_title>An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States</brief_title>
	<detailed_description>The purpose of this study is to evaluate the safety and efficacy of the long-term treatment of entacapone in patients with Parkinson's disease with end-of-dose wearing-off.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Attended the Phase IIb study Able to fill out the patient diary Serious heart, pulmonary, renal, hepatic or gastrointestinal disease Dementia symptoms Pregnant or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Parkinson's disease, end-of -dose wearing-off, entacapone</keyword>
</DOC>